Modalis Therapeutics Corporation (4883.T)
JPY 86.0
(-1.15%)
JPY 86.0
(-1.15%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.02 Billion JPY | -35.27% |
| 2022 | 3.12 Billion JPY | -48.43% |
| 2021 | 6.06 Billion JPY | -3.31% |
| 2020 | 6.27 Billion JPY | 59.4% |
| 2019 | 3.93 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.55 Billion JPY | -23.04% |
| 2024 Q2 | 1.4 Billion JPY | -9.59% |
| 2023 FY | 2.02 Billion JPY | -35.27% |
| 2023 Q3 | 2.17 Billion JPY | -23.69% |
| 2023 Q1 | 2.89 Billion JPY | -7.34% |
| 2023 Q4 | 2.02 Billion JPY | -7.03% |
| 2023 Q2 | 2.85 Billion JPY | -1.51% |
| 2022 Q3 | 4.88 Billion JPY | 0.0% |
| 2022 Q4 | 3.12 Billion JPY | -35.97% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 36.57 Billion JPY | 94.461% |
| Takeda Pharmaceutical Company Limited | 15108.79 Billion JPY | 99.987% |
| Sumitomo Pharma Co., Ltd. | 907.5 Billion JPY | 99.777% |
| Shionogi & Co., Ltd. | 1416.91 Billion JPY | 99.857% |
| Wakamoto Pharmaceutical Co.,Ltd. | 15.42 Billion JPY | 86.863% |
| Nippon Shinyaku Co., Ltd. | 263.4 Billion JPY | 99.231% |
| Kaken Pharmaceutical Co., Ltd. | 171.62 Billion JPY | 98.82% |
| Eisai Co., Ltd. | 1393.79 Billion JPY | 99.855% |
| Morishita Jintan Co., Ltd. | 17.18 Billion JPY | 88.21% |
| Hisamitsu Pharmaceutical Co., Inc. | 328.77 Billion JPY | 99.384% |
| Mochida Pharmaceutical Co., Ltd. | 158.8 Billion JPY | 98.724% |
| Fuso Pharmaceutical Industries,Ltd. | 76.46 Billion JPY | 97.35% |
| Nippon Chemiphar Co., Ltd. | 49.54 Billion JPY | 95.911% |
| Tsumura & Co. | 428.25 Billion JPY | 99.527% |
| Kissei Pharmaceutical Co., Ltd. | 260.92 Billion JPY | 99.224% |
| Torii Pharmaceutical Co., Ltd. | 133.43 Billion JPY | 98.482% |
| Towa Pharmaceutical Co., Ltd. | 430.65 Billion JPY | 99.53% |
| Fuji Pharma Co., Ltd. | 85.33 Billion JPY | 97.626% |
| Zeria Pharmaceutical Co., Ltd. | 150.53 Billion JPY | 98.654% |
| KYORIN Holdings, Inc. | 177.67 Billion JPY | 98.86% |
| Taiko Pharmaceutical Co.,Ltd. | 15.04 Billion JPY | 86.535% |
| Daito Pharmaceutical Co.,Ltd. | 77.7 Billion JPY | 97.393% |
| SymBio Pharmaceuticals Limited | 15.35 Billion JPY | 86.804% |
| MedRx Co., Ltd | 2.05 Billion JPY | 1.271% |
| Mizuho Medy Co.,Ltd. | 18.94 Billion JPY | 89.308% |
| Solasia Pharma K.K. | 2.55 Billion JPY | 20.552% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 93.31 Billion JPY | 97.829% |
| Sawai Group Holdings Co., Ltd. | 382.02 Billion JPY | 99.47% |
| Cyfuse Biomedical K.K. | 4.21 Billion JPY | 51.933% |
| Toho Holdings Co., Ltd. | 773.42 Billion JPY | 99.738% |
| Koa Shoji Holdings Co.,Ltd. | 32 Billion JPY | 93.67% |